Eliminating health disparities between races is a goal of many groups and organizations, but a team of sociologists suggests that finding the reasons for the differences in the timing of black and white deaths may be trickier than once thought. Interventions to reduce this disparity may be more effective if they target sex, as well as race. "With regard to policy, our results indicate the importance of sex-specific intervention to reduce racial disparities," the researchers said. "In the case of HIV/AIDS, for example, there is greater potential for significant reduction of the racial gap when men are targeted. The opposite is true for heart disease and diabetes, where interventions focused on women are more likely to narrow the gap."
17 December 2014 | Science Daily
Although the majority of developing countries do not yet offer viral load testing on a routine basis, the use of HIV viral load monitoring is rapidly gathering pace in most developing countries. Which questions remain in further scaling up this gold standard for HIV treatment monitoring in these countries? Médecins Sans Frontières (MSF) is releasing Achieving Undetectable, the latest in a series of issue briefs and reports on access to viral load monitoring in resource-limited settings.
15 December 2014 | MSF
Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”
12 December 2014 | Chimicles & Tikellis press release
San Francisco is already making progress when it comes to HIV prevention, treatment and retention. In 2006, San Francisco had 517 new HIV cases; by 2013, that number dropped to 359, a 30 percent decrease. The number of deaths almost halved between 2006 and 2013, going from 327 to 182. Additionally, compared to the United States, San Francisco is faring better in multiple aspects of the HIV care continuum: in 2012, 82 percent of HIV positive individuals in the U.S. were aware of their status; in San Francisco, that number was 94 percent.
11 December 2014 | Huffington Post
Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.
10 December 2014 | Science Daily
Since the start of President Obama’s Administration, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has achieved a four-fold increase and is now providing 7.7 million people with life-saving antiretroviral (ARV) treatment worldwide. Despite this, only 1 in 4 of the 3.2 million children living with HIV/AIDS worldwide are today receiving treatment.
09 December 2014 | US Department of State
Myanmar has pledged to provide free treatment to around half of the country’s patients affected by HIV and AIDS by 2016, as civil society groups called on the government to increase efforts to meet upcoming global eradication targets on World AIDS Day.
05 December 2014 | Radio Free Asia
The license being granted to Mylan extends to 112 countries, which together account for more than 30 million people living with HIV, representing 84% of those infected globally.
04 December 2014 | Mylan press release
Knowing your status is the key to ending the Aids pandemic but still too few South Africans take the step to get tested for HIV. A report in the Mail & Guardian this week less than a third of the country's 35-million sexually active people get tested for HIV annually.
03 December 2014 | AllAfrica.com
Since 2010, UNITAID’s investments in the MPP have yielded 2.6 times the value of its funding through such licensing deals. Between 2010 and 2028, this return on investment is projected to generate between $1.18 - $1.4 billion in savings due to price reductions through generic product manufacturing of key HIV medicines.
02 December 2014 | UNITAID